Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002156 · ClinicalTrials.gov registry record · Phase 2
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT00002156 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 194 participants.
The verdict
NCT00002156, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.
Interventions
- DRUG Ganciclovir
- DRUG Fomivirsen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002156
The ClinicalTrials.gov registry entry for NCT00002156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ganciclovir is the first listed.
NCT00002156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002156 about?
NCT00002156 is a clinical study titled "A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )". To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.
What is the current status of trial NCT00002156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants.
What interventions are being tested in trial NCT00002156?
The interventions under investigation include: Ganciclovir (DRUG), Fomivirsen sodium (DRUG).
Who is sponsoring clinical trial NCT00002156?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.